USE OF URISAN IN PATIENTS WITH GOUT
https://doi.org/10.14412/1996-7012-2010-585
Abstract
Objective: to evaluate the safety, tolerance, and efficacy of the herbal complex Urisan used in patients with gout within the Russian multicenter
study.
Subjects and methods. Thirty males aged 34 to 56 years with a valid diagnosis of gout after S.L. Wallace and a 1-7-year (mean 4,8 years)
history of the disease were examined at the Rheumatology Unit of a Kursk regional hospital. Nineteen and 11 patients were stated to have tophaceous
and nontophaceous gout, respectively. The total number of involved joints ranged from 3 to 10 (mean 4,6 joints). The study included
patients with interictal gout. All the patients took Urisan in a full dose of 2 capsules (550 mg) twice daily for a month.
Results. Prior to Urisan therapy, the mean serum level of uric acid (UA) was 569,5±102,4 ⎧mol/l; daily UA excretion averaged 4769,8 ⎧mol/l.
Urisan therapy reduced UA levels by an average of 120 ⎧mol/l and increased daily urinary UA excretion by an average of 198,8 цmol/l.
Conclusion. Urisan used against gout for 30 days causes an average 21% reduction in the serum levels of UA and a 4,1% increase in its urinary
excretion. There were no exacerbations of gout during Urisan therapy.
study.
Subjects and methods. Thirty males aged 34 to 56 years with a valid diagnosis of gout after S.L. Wallace and a 1-7-year (mean 4,8 years)
history of the disease were examined at the Rheumatology Unit of a Kursk regional hospital. Nineteen and 11 patients were stated to have tophaceous
and nontophaceous gout, respectively. The total number of involved joints ranged from 3 to 10 (mean 4,6 joints). The study included
patients with interictal gout. All the patients took Urisan in a full dose of 2 capsules (550 mg) twice daily for a month.
Results. Prior to Urisan therapy, the mean serum level of uric acid (UA) was 569,5±102,4 ⎧mol/l; daily UA excretion averaged 4769,8 ⎧mol/l.
Urisan therapy reduced UA levels by an average of 120 ⎧mol/l and increased daily urinary UA excretion by an average of 198,8 цmol/l.
Conclusion. Urisan used against gout for 30 days causes an average 21% reduction in the serum levels of UA and a 4,1% increase in its urinary
excretion. There were no exacerbations of gout during Urisan therapy.
About the Authors
L A KnyazevaI I Goryaynov
E A Masalova
L I Knyazeva
A V Prasolov
LA Knyazeva
I I Goryainov
E A Masalova
L I Knyazeva
A V Prasolov
References
1. <div><p>Ильина А.Е., Барскова В.Г. Применение урисана при подагре. Совр ревматол 2008;1:81-3.</p><p>Ильина А.Е., Барскова В.Г. Как оптимизировать лечение больных подагрой с хроническим артритом. В фокусе - Урисан. Совр ревматол 2009;1:49-50.</p><p>Ильина А.Е., Барскова В.Г. Значение диеты и биологически активных добавок к пище при подагре. Совр ревматол 2008;1:58-63.</p><p>Frondoza C.G., Sohrabi A., Polotsky A. et al. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim 2004;40:95-101.</p><p>Do Monte F.H., dos Santos J.G., Russi M. et al. Antinociceptive and anti-inflammatory properties of the hydroalcoholic extract of stems from Equisetum arvense L. in mice. Pharmacol Res 2004;49(3):239-43.</p><p>Yadav P.N., Liu Z., Rafi M.M. A diarylheptanoid from lesser galangal (Alpinia officinarum) inhibits proinflammatory mediators via inhibition of mitogen- activated protein kinase, p44/42, and transcription factor nuclear factor-kappa B. J Pharmacol Exp Ther 2003;305(3):925-31.</p></div><br />
Review
For citations:
Knyazeva LA, Goryaynov II, Masalova EA, Knyazeva LI, Prasolov AV, Knyazeva L, Goryainov II, Masalova EA, Knyazeva LI, Prasolov AV. USE OF URISAN IN PATIENTS WITH GOUT. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(1):39-40. (In Russ.) https://doi.org/10.14412/1996-7012-2010-585
Views:
4429
Email this article 